Phase 4
N=315
PV-Isolation With the Cryoballoon Versus RF:a Randomized Controlled Prospective Non-inferiority Trial (FreezeAF)
Atrial Fibrillation
Bottom Line
View on ClinicalTrials.gov: NCT00774566 ↗Enrolled (actual)
315
Serious AEs
4.1%
Results posted
Apr 2021
Primary outcome: Primary: Combined Endpoint Out of: Absence of Atrial Arrhythmias and Absence of Persistent Complications at Six Months After the Index Procedure — 99; 98 Participants
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 4
- Interventions
- PV-Isolation RF (Procedure); PV-Isolation Cryo (Procedure)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Staedtisches Klinikum Karlsruhe
- Primary completion
- Dec 2014
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Combined Endpoint Out of: Absence of Atrial Arrhythmias and Absence of Persistent Complications at Six Months After the Index Procedure |
99; 98 | — |
| PRIMARY Combined Endpoint Out of: Absence of Atrial Arrhythmias and Absence of Persistent Complications Twelve Months After Procedure. |
103; 105 | — |
| SECONDARY Long-term Clinical Success |
141; 141 | — |
| SECONDARY Total Radiation Exposure |
50.0; 61.5 | — |
| SECONDARY Total Procedure Duration |
162.0; 151.0 | — |
| SECONDARY Major Adverse Events |
147; 144; 12; 12 | — |
| SECONDARY Mid-term Clinical Success |
154; 150 | — |
Summary
This study is designed as a randomized, controlled, prospective, non-inferiority clinical trial, where the efficacy and safety of the cryoballoon ablation system (CE certificated) will be compared to the standard ablation technique (segmental isolation of the pulmonary veins) with radiofrequency energy. The primary study aim is to investigate whether the new cryoballoon ablation catheter system (Arctic Front CryoAblation Catheters, FlexCath Steerable Sheath, CryoCath Technologies Inc., Montreal, Canada) is at least as effective as radiofrequency (RF) segmental isolation in electrically disconnecting the pulmonary veins (PV) for the treatment of paroxysmal atrial fibrillation (AF) with respect to the absence of atrial arrhythmias without persistent complications after six and twelve months. Furthermore, the differences in terms of procedural complications such as pulmonary vein stenosis, phrenic nerve injuries, cerebrovascular accidents (CVA), pericardial tamponade, pain scores during the procedure, levels of cardiac inflammatory markers are compared between the treatment groups. The short and long-term clinical success as well as the costs of both systems will also be evaluated.
Eligibility Criteria
Inclusion Criteria
- Documented paroxysmal PAF: PAF diagnosis, 2 episodes of PAF within the last 3 months, at least 1 episode of PAF must be documented.
- Age 18-75
- Documented effectiveness failure of at least 1 AAD including beta-blockers
Exclusion Criteria
- AAD usage 55 mm
- LA thrombus
- Previous LA ablation/surgery, structural heart disease, heart failure class III-IV
- Hypertrophic cardiomyopathy
- Mitral prosthesis
- Unstable angina
- Uncontrolled hyperthyroidism
- Stroke or TIA within 6 months
- Myocardial infarction within 2 months
- Cardiac surgery within 3 months
- Thrombocytosis, thrombocytopenia
- Any condition contraindicating chronic anticoagulation
- EF < 40%
- Pregnancy
- Life expectancy < 1 year
Data sourced from ClinicalTrials.gov (NCT00774566). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.